An uncommon cause of anaemia: Sheehan“s syndrome.

Melchardt, T; Namberger, K; Weiss, L; Egle, A; Faber, V; Greil, R; WIEN KLIN WOCHENSCHR. 2010; 122(23-24): 717-719.

The impact of storage effects in biobanks on biomarker discovery in systems biology studies

Balasubramanian, R; Muller, L; Kugler, K; Hackl, W; Pleyer, L; Dehmer, M; Graber, A BIOMARKERS. 2010; 15(8): 677-683.

High expression and functional signalling implicate CXCR4 in T-PLL biology

Weit, N; Hopfinger, G; Pflug, N; Becker, H; Gleim, C; Lilienthal, N; Hallek, M; Herling, M ONKOLOGIE. 2011; 34: 132-133.

R-CHOP plus thalidomide for previously untreated patients with mantle cell lymphoma (AGMT NHL-11 trial)

Drach, J; Hopfinger, G; Fridrik, M; Greil, R; Thaler, J; Willenbacher, W; Lang, A; Jager, U; Raderer, M ONKOLOGIE. 2011; 34: 75-75.

Peripheral T-cell lymphomas (PTCL)-have we made any progress?

Hopfinger, G ONKOLOGIE. 2011; 34: 15-15.

Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia

Holler, C; Zaborsky, N; Hofbauer, JP; Kocher, T; Trapin, D; Asslaber, D; Greil, R; Egle, A BLOOD. 2011; 118(21): 365-365.

CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL

Egle, A; Pinon-Hofbauer, J; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R ANN ONCOL. 2011; 22: 144-144.

Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia

Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Denk, U; Pinon-Hofbauer, J; Egle, A; Kocher, T; Steurer, M; Greil, R; Merkel, O ONKOLOGIE. 2011; 34: 141-141.

PHASE II TRIAL OF CONTINUOUS SUNITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA (SURGE 01-07)

Hutterer, M; Martha, N; Sabine, E; Thaddaus, G; Florian, S; Christine, M; Stefan, O; Richard, G; Martin, M; Johanna, B; Jochen, T; Ullrich, H; Wolfgang, W; Peter, V; Gunther, S NEURO-ONCOLOGY. 2011; 13: 88-88.

Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib

Muller, MC; le Coutre, P; Gattermann, N; Scheid, C; Al-Ali, HK; Ottmann, OG; Duyster, J; Blumenstengel, K; Brummendorf, TH; Greil, R; Chalandon, Y; Valent, P; Stegelmann, F; Kneba, M; Schafhausen, P; Saussele, S; Frank, O; Larson, RA; Saglio, G; Hochhaus, A; Lange, T ONKOLOGIE. 2011; 34: 266-266.